Acute Repetitive Seizures Market Size

Acute Repetitive Seizures Market Size

The global acute repetitive seizures market in 2023 was valued at USD 2.7 billion and is poised to grow at 12.4% CAGR over the forecast period. The market is growing significantly due to the increasing prevalence of epilepsy and advancements in rescue therapies.

According to the World Health Organization, approximately 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Similarly, the Centers for Disease Control and Prevention (CDC) reports that about 3.4 million people in the U.S., including 470,000 children, have active epilepsy, highlighting the substantial potential market for these therapies.
 

Furthermore, the development of intranasal formulations, such as USL-261 (intranasal midazolam) and NRL-1 (intranasal diazepam), has significantly impacted the market. These newer therapies provide fast, non-invasive administration, enhancing accessibility for patients and caregivers, particularly in home settings. The convenience and simplicity of intranasal therapies are driving their adoption, as they enable quick intervention without requiring medical supervision, thereby contributing to market growth.
 

Acute repetitive seizures (ARS), also known as seizure clusters or flurries, refer to a series of seizures that occur within a short time frame, usually between 24 and 48 hours, with the risk of escalating into status epilepticus—a life-threatening condition. ARS is common among epilepsy patients, particularly those who struggle to maintain full control over their seizures, making it a critical focus for treatment solutions. Management of ARS typically involves rescue medications, such as benzodiazepine drugs (e.g., diazepam, midazolam), administered to halt seizure activity and prevent escalation. Treatment aims to reduce seizure frequency, prevent further clusters, and protect against complications.